SummaryRMgm-5142
|
||||||||
*RMgm-5142| Successful modification | The parasite was generated by the genetic modification |
| The mutant contains the following genetic modification(s) | Gene disruption |
| Reference (PubMed-PMID number) |
Reference 1 (PMID number) : 34959491 |
| MR4 number | |
| top of page | |
| Parent parasite used to introduce the genetic modification | |
| Rodent Malaria Parasite | P. berghei |
| Parent strain/line | P. berghei ANKA |
| Name parent line/clone | P. berghei ANKA 2.34 |
| Other information parent line | P. berghei ANKA 2.34 is a cloned, gametocyte producer line of the ANKA strain (PubMed: PMID: 15137943). |
| top of page | |
| The mutant parasite was generated by | |
| Name PI/Researcher | Hirai M, Mita T |
| Name Group/Department | Department of Tropical Medicine and Parasitology, Faculty of Medicine |
| Name Institute | Juntendo University |
| City | Tokyo |
| Country | Japan |
| top of page | |
| Name of the mutant parasite | |
| RMgm number | RMgm-5142 |
| Principal name | Pb103(-) |
| Alternative name | |
| Standardized name | |
| Is the mutant parasite cloned after genetic modification | Yes |
| top of page | |
| Phenotype | |
| Asexual blood stage | Not different from wild type |
| Gametocyte/Gamete | Not different from wild type |
| Fertilization and ookinete | Absence of ookinete formation (due to abortion of zygote development). |
| Oocyst | Absence of ookinete and oocyst formation |
| Sporozoite | Absence of oocyst and sporozoite formation |
| Liver stage | Not tested |
| Additional remarks phenotype | Mutant/mutation Phenotype Other mutants |
Disrupted: Mutant parasite with a disrupted gene| top of page | |||||||||||||||||||||||||
| Details of the target gene | |||||||||||||||||||||||||
| Gene Model of Rodent Parasite | PBANKA_1134900 | ||||||||||||||||||||||||
| Gene Model P. falciparum ortholog | PF3D7_1358600 | ||||||||||||||||||||||||
| Gene product | zinc finger protein, putative | ||||||||||||||||||||||||
| Gene product: Alternative name | Pb103 | ||||||||||||||||||||||||
| top of page | |||||||||||||||||||||||||
| Details of the genetic modification | |||||||||||||||||||||||||
| Inducable system used | No | ||||||||||||||||||||||||
| Additional remarks inducable system | |||||||||||||||||||||||||
| Type of plasmid/construct used | (Linear) plasmid double cross-over | ||||||||||||||||||||||||
| PlasmoGEM (Sanger) construct/vector used | No | ||||||||||||||||||||||||
| Modified PlasmoGEM construct/vector used | No | ||||||||||||||||||||||||
| Plasmid/construct map | |||||||||||||||||||||||||
| Plasmid/construct sequence | |||||||||||||||||||||||||
| Restriction sites to linearize plasmid | |||||||||||||||||||||||||
| Partial or complete disruption of the gene | Complete | ||||||||||||||||||||||||
| Additional remarks partial/complete disruption | |||||||||||||||||||||||||
| Selectable marker used to select the mutant parasite | hdhfr | ||||||||||||||||||||||||
| Promoter of the selectable marker | pbdhfr | ||||||||||||||||||||||||
| Selection (positive) procedure | pyrimethamine | ||||||||||||||||||||||||
| Selection (negative) procedure | No | ||||||||||||||||||||||||
| Additional remarks genetic modification | To generate a construct for Pb103 gene disruption, two PCR fragments covering 500 bp of the 50 and 30 UTRs of the Pb103 gene were amplified by two pairs of primers, Pb03(-)- F1/Pb03(-)-R1 and Pb03(-)- F2/Pb03(-)-R2, respectively, and P. berghei genomic DNA as a template. Then, each PCR product was conjugated to either end of PstI/HindIII digested pL0006 (MRA-775; BEI Resources.) by fusion PCR using primer Pb03(-)-F1/Pb03(-)-R2 | ||||||||||||||||||||||||
| Additional remarks selection procedure | |||||||||||||||||||||||||
|
Primer information: Primers used for amplification of the target sequences
![]() Primer information: Primers used for amplification of the target sequences
| |||||||||||||||||||||||||
| top of page | |||||||||||||||||||||||||